Spatial Proteomics study for TEN Marked enrichment of type I and II interferon and STAT1 activation Pathways suggests benefit for JAKi in this condition Clinical response in case photos, suggests benefit of pursuing clinical trial Year in Review #ACR24 Bridges @RheumNow https://t.co/K34lbnenRH

Like we've seen in many parts of the world, RA prescribing in Germany is moving away from JAKi, in response to regulatory safety warnings. Whether all of this is appropriate or not, we'll have to see... #ACR24 ABST0503 @RheumNow https://t.co/VSqdCz6zc5

#ACR24 Year in Review: 💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨) 💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?) 💡 High risk of CV events within 30 days of gout… https://t.co/XF63zr6lk4 https://t.co/oRNri66Il9

Synovial fibroblast gene expression Neutron-4 - plays role in axonal outgrowth, affects pain-sensitive neurons May help explain pain in RA, possible targets Year in Review #ACR24 Bridges @RheumNow https://t.co/kpDVKh0C9O

Role of X chromosome in autoimmune disease? SLE increased in Klinefelter (XXY), decreased in Turner’s (XO) X chromosome inactivation with Xist Inductively transgenic expression of Xist in male mice induces autoantibodies Year in Review #ACR24 Bridges @RheumNow https://t.co/M88f0v0kpe

Amazing review @NamrataRheum on the important role the rheumatologist can play to improve the care of our older patients! Don’t forget the 5Ms! 🧠Mind (cog/mood) 💊Medication (PIM) 🏃‍♀️Mobility 👉Multi-complexity 💪🏻Matters most (pt priority) @RheumNow #ACR24 #gerirheum https://t.co/0Iv4TdS8AX

CV risk factors in rheumatic dz patients start in childhood. Patients with PMH of Kawasaki disease are at risk for rca/lmca aneurysms, thrombosis and stroke. Important to consider this with our history taking when pediatric patients transition to adult care! @RheumNow #ACR24 https://t.co/CIp8PjW4vD

EGPA: To RTX or not to RTX? French MAINRITSEG trial underway to determine utility of RTX vs. AZA maintenance therapy Huge anticipation for these results, hopefully next year! #ACR24 @RheumNow https://t.co/POelLpirrI

SCN9A: Mutations associated with primary erythromelalgia, loss of fxn in congenital inability to experience pain Target for OA? Nav1.7 expressed in human OA chondrocytes Blocking in mice- decr structural jt damage, incr mouse movement Bridges Year in Review #ACR24 @RheumNow https://t.co/AKViXGfDa6

Hot off the racks: The MITIGATE trial is the 1st RCT for IgG4-RD showing that Inebilizumab significantly reduced flare rates vs PbO by depleting CD19-targeted B cells Game changer? Year in review. @RheumNow #ACR24 @rheumarhyme @marklagacmd @idatan @ljdado https://t.co/CZvdrymIyr

Treatment alert for Sjogrens TWINSS study: Iscalimab CD40/CD40L monoclonal Ab: Improves disease activity Also helps fatigue and sicca, not pain Dazodalibep - CD40L antagonist also reduce symptoms/disease activity Year in Review #ACR24 Pillinger @RheumNow https://t.co/WjHuEpm9XW